Intervention Review

You have free access to this content

Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation

  1. Mohamed Kharfan-Dabaja1,2,
  2. Rahul Mhaskar3,
  3. Tea Reljic3,
  4. Joseph Pidala1,
  5. Janelle B Perkins4,
  6. Benjamin Djulbegovic1,5,
  7. Ambuj Kumar3,*

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 25 JUL 2014

Assessed as up-to-date: 17 MAR 2014

DOI: 10.1002/14651858.CD010280.pub2


How to Cite

Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database of Systematic Reviews 2014, Issue 7. Art. No.: CD010280. DOI: 10.1002/14651858.CD010280.pub2.

Author Information

  1. 1

    H. Lee Moffitt Cancer Center, Division of Oncologic Sciences, University of South Florida, Department of Blood and Marrow Transplantation, Tampa, Florida, USA

  2. 2

    American University of Beirut, Division of Hematology-Oncology and Bone Marrow Transplantation Program, Beirut, Lebanon

  3. 3

    University of South Florida, Center for Evidence Based Medicine and Health Outcomes Research, Tampa, Florida, USA

  4. 4

    Division of Oncologic Sciences, University of South Florida, Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida, USA

  5. 5

    University of South Florida, USF Clinical Translational Science Institute, Departments of Medicine, Hematology and Health Outcome Research, Tampa, Florida, USA

*Ambuj Kumar, Center for Evidence Based Medicine and Health Outcomes Research, University of South Florida, Tampa, Florida, USA. akumar1@health.usf.edu. drambujkr@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 25 JUL 2014

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgments about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Mycophenolate mofetil versus methotrexate, Outcome 1 Prevention of acute GVHD grade II to IV.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Mycophenolate mofetil versus methotrexate, Outcome 2 Overall survival.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Mycophenolate mofetil versus methotrexate, Outcome 3 Time to neutrophil engraftment.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Mycophenolate mofetil versus methotrexate, Outcome 4 Time to platelet engraftment.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Mycophenolate mofetil versus methotrexate, Outcome 5 Incidence of relapse.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Mycophenolate mofetil versus methotrexate, Outcome 6 Nonrelapse mortality.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Mycophenolate mofetil versus methotrexate, Outcome 7 Prevention of chronic GVHD.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Mycophenolate mofetil versus methotrexate, Outcome 8 Incidence of severe mucositis.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Mycophenolate mofetil versus methotrexate, Outcome 9 Use of total parenteral nutrition.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Mycophenolate mofetil versus methotrexate, Outcome 10 Incidence of narcotic use for pain control.